
Grown, Not Scraped: Orakl, Patient Avatars and the Race to Predict Phase 2
Dr. Dereck Mush, MD, MBAVenture fund
Verve Ventures focuses on three themes: resilience in energy and resources, the future of computing, and frontiers in health and bio, where it says biology, engineering and data are converging to make care more precise and accessible. Its investors include family offices, wealth managers, institutions, founders and senior executives. Portfolio companies include Q.ANT, which builds optical processors for AI, and Memo Therapeutics, which finds ultra rare antibodies and is listed as an exit. Verve was an existing investor in Orakl Oncology and returned for its $34 million Series A in November 2026, jointly led by Norrsken VC and Singular. Orakl grows patient tumors in the lab to predict how cancer drugs will perform.
Verve Ventures invests in European deep tech founders at Pre-seed and Seed, with initial tickets of €1 million to €5 million.
How Verve Ventures got here, step by step.
2026
Returning investor in Orakl Oncology's $34M Series A.
Venture fund
Venture fund
Venture fund
Venture fund
Venture fund
Venture fund

Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBAKeep exploring